Kanjo Health

Last updated on

Visit website

NHS Problem

The global prevalence of attention deficit hyperactivity disorder (ADHD) in children is estimated to be around 5%. Timely interventions mitigate risks and improve outcomes potentially saving £33.5 million to £38 million per year. Despite this, parents are known to face prejudice and long waiting lists which vary significantly from 5 weeks to 5 years. In addition to the vast wait time, 20% of children currently diagnosed with ADHD have been misdiagnosed and over 80% have been underdiagnosed.  

The Solution

Kanjo personalises the care pathway before it starts. Leveraging thousands of data points, we combine generative AI and hierarchical Bayesian networks to create a suite of clinical tools and pre-diagnostic insight platforms that will be more accurate than ever before, starting with ADHD and Autism. 

Impact

Kanjo leverages cutting-edge generative AI and hierarchical Bayesian networks to innovate and improve the diagnostic journey from start to finish.  

  • Pre-diagnosis Phase: Providing families with expert-written, personalised content, alleviating the need for unreliable internet searches, and offering tailored support through the diagnosis process.  
  • During Diagnosis: Integrating into existing clinical pathways, streamlining intake procedures by automating standardised assessments.

For clinicians, Kanjo offers invaluable pre-clinical objective data, modernising diagnostic procedures and minimising subjective biases.

  • Efficiency: By digitising assessments, Kanjo reduces bottlenecks in the diagnostic process, empowering clinicians to see more patients per day.
  • Cost-Effectiveness: Cutting down the 40-hour diagnostic journey per case translates to improved NHS resource allocation, enhancing access to timely interventions.
  • Accuracy: Kanjo’s algorithm, backed by extensive data points, calculates risk scores for ADHD influencing factors, mitigating the likelihood of misdiagnoses, and ensuring precise identification.